164514EGP
- Active ingredient
- atezolizumab
- Strength
- 1200 mg
- Form
- vial
- Manufacturer
- f.hoffman la roche
- Route
- injection
Uses
PD-L1 inhibitor used for multiple cancers including selected non-small cell lung cancer and other approved malignancies.
Do not use if
No specific contraindications are listed in the referenced labeling.
Side effects
May cause fatigue, decreased appetite, infusion reactions, and severe immune-mediated adverse reactions affecting various organs.
Warnings
Monitor for immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies, and infusion-related reactions.
How it works
Blocks PD-L1 interaction with immune receptors, enhancing anti-tumor immune responses.
Storage
Store refrigerated at 2–8°C in the original carton. Do not freeze or shake.